MENS Stock Analysis: Buy, Sell, or Hold?
MENS - Jyong Biotech Ltd. Ordinary Shares
$1.99
-0.02 (-1.00%)
βΌ
5d:
-12.33%
30d:
-2.45%
90d:
+16.72%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When MENS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR STABILIZATION: MENS is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
βΈοΈ WAIT FOR STABILIZATION: MENS is down 12.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MENS is currently trading at $1.99, which is considered oversold relative to its 30-day fair value range of $2.03 to $2.26.
Technical Outlook: Technically, MENS is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MENS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MENS is showing sideways momentum. The price is currently testing key support at $1.97. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MENS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.03 -
$2.26
Company Quality Score
35/100
(SELL)
Options IV Signal
4th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
63.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 4th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- WARNING: Composite score 35/100 in the bottom quintile β this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.03 -
$2.26
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
Β±$0.38
(19.1%)
Support & Resistance Levels
Support Level
$1.97
Resistance Level
$2.44
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Share & Embed Analysis
Last updated: September 13, 2026 1:49 AM ET
Data refreshes hourly during market hours. Next update: 2:49 AM
Data refreshes hourly during market hours. Next update: 2:49 AM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MENS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical⦠|
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut⦠|
STRONG BUY
16 analysts |
$29 | 41 HOLD |